E-resources
Peer reviewed
Open access
-
Figueroa, Amparo; Ali, Kashif; Berman, Gary; Zhou, Honghong; Deng, Weiping; Patel, Monali; Girard, Bethany; Yeakey, Anne; Slobod, Karen; Priddy, Frances; Miller, Jacqueline; Das, Rituparna
Open forum infectious diseases, 11/2023, Volume: 10, Issue: Supplement_2Journal Article
Abstract Background Increased community COVID-19 cases prompted the clinical evaluation of an mRNA-1273 booster dose (BD) in TeenCOVE adolescent participants (12-17 years) who received a 2-dose mRNA-1273 primary series. At ≥5 months after dose 2 (coinciding with the omicron wave peak in Jan 2022), TeenCOVE participants were offered an optional 50-µg mRNA-1273 BD. Here, we inferred BD effectiveness in adolescents by demonstrating non-inferiority (NI) of neutralizing antibody (nAb) responses post-BD vs young adults (18-25 years) post-dose 2 of 100-μg mRNA-1273 primary series in the pivotal phase 3 COVE study, where efficacy was established. Methods Up to 6 months post-BD, 1405 participants were monitored for COVID-19 and safety (solicited adverse reactions ≤7 days post-BD; unsolicited AEs ≤28 days post-BD; and medically attended, serious SAEs, of special interest AESI, or leading to discontinuation throughout study). At Day 29 post-BD, nAb geometric mean concentrations (GMCs) were measured against ancestral D614G SARS-CoV-2 spike protein. Binding antibodies (bAbs) against spike protein of ancestral strain or alpha, beta, delta, and gamma variants were measured. Results An mRNA-1273 BD was generally well-tolerated; reactogenicity profiles were consistent to the phase 3 COVE study in young adults. There were no severe COVID-19 cases, deaths, or investigator-reported vaccine-related SAEs or AESIs. In pre-booster SARS-CoV-2 negative participants, the ratio of adolescent (n=264) BD-Day 29 GMC (7102; 95% CI, 6553.2-7696.8) to young adult (n=294) Day 57 GMC (1400.4; 1272.7-1541.0) was 5.1 (4.5-5.7), meeting NI criterion for GMR (Fig 1; Table 1). The group difference in seroresponse rate (SRR) between adolescents and young adults was 0.7% (95% CI, -0.8 to 2.4), meeting NI criterion for SRR difference (Table 1). Robust bAb responses were observed, including against variants. Conclusion Effectiveness of an mRNA-1273 BD against COVID-19 in adolescents was inferred by successful immunobridging to young adults in the pivotal phase 3 trial. The benefits of variant-containing mRNA-1273 boosters demonstrated in adults is also anticipated to be conferred to adolescents. The overall benefit-risk profile of an mRNA-1273 BD is favorable in adolescents. Disclosures Amparo Figueroa, MD, MPH, Moderna, Inc.: salary|Moderna, Inc.: Stocks/Bonds Gary Berman, MD, Moderna, Inc.: Grant/Research Support Honghong Zhou, Ph.D., Moderna, Inc.: salary|Moderna, Inc.: Stocks/Bonds Weiping Deng, PhD, Moderna, Inc.: salary|Moderna, Inc.: Stocks/Bonds Monali Patel, MS, Moderna, Inc.: salary|Moderna, Inc.: Stocks/Bonds Bethany Girard, Ph.D., Moderna, Inc.: salary|Moderna, Inc.: Stocks/Bonds Anne Yeakey, MD, Moderna, Inc.: Advisor/Consultant Karen Slobod, MD, Moderna, Inc.: Advisor/Consultant Frances Priddy, MD, MPH, Moderna, Inc.: Salary|Moderna, Inc.: Stocks/Bonds Jacqueline Miller, MD, Moderna, Inc.: salary|Moderna, Inc.: Stocks/Bonds Rituparna Das, M.D., Moderna, Inc.: Salary|Moderna, Inc.: Stocks/Bonds
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.